Literature DB >> 22089328

Rasburicase for hyperuricemia in hemolytic uremic syndrome.

Alisa A Acosta1, Ronald J Hogg.   

Abstract

BACKGROUND: Acute kidney injury (AKI) with elevated serum uric acid (UA) levels has been reported in patients with hemolytic uremic syndrome (HUS). AKI is thought to result from tubular obstruction by UA crystals. Inducing a diuresis may ameliorate the oligoanuria in such patients. We describe a child with HUS in whom reducing UA with fluids and rasburicase appeared to accelerate the recovery of renal function. CASE-DIAGNOSIS/TREATMENT: A 9-month-old Caucasian male infant presented with 6 days of diarrhea, 3 days of vomiting, and 24 h of oliguria. On admission, hemoglobin was 8.3 g/dL, platelet count 36,000/L, blood urea nitrogen 73 mg/dL, and serum creatinine (SCr) 2.7 mg/dL. Diarrhea-associated HUS was diagnosed. The day after admission, SCr was 2.9 mg/dL and UA 12.3 mg/dL. On hospital day 2, he received a dose of intravenous rasburicase 0.18 mg/kg, and less than 12 h later, the UA had fallen to 0.3 mg/dL. The SCr level also started to fall, and urine output progressively increased without the use of diuretics. Renal function continued to improve, and the UA level remained normal despite ongoing hemolysis requiring a second red blood cell transfusion on hospital day 5. The patient was discharged on hospital day 7 in good physical condition. Two months later, he was in good health, with a SCr level of 0.2 mg/dL and UA of 4.2 mg/dL.
CONCLUSIONS: We postulate that aggressive management of the high serum UA level with rasburicase and fluid hydration accelerated the recovery of our patient. Further studies are needed to determine the role of rasburicase in the treatment of hyperuricemia in patients with HUS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089328     DOI: 10.1007/s00467-011-2047-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  14 in total

1.  Hyperuricemia in the hemolytic-uremic syndrome.

Authors:  B S Kaplan; P D Thomson
Journal:  Am J Dis Child       Date:  1976-08

2.  Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.

Authors:  Nakysa Hooman; Hasan Otukesh
Journal:  Iran J Kidney Dis       Date:  2011-03       Impact factor: 0.892

3.  Decreased necessity for dialysis with loop diuretic therapy in hemolytic uremic syndrome.

Authors:  E Rousseau; N Blais; S O'Regan
Journal:  Clin Nephrol       Date:  1990-07       Impact factor: 0.975

4.  A micropuncture study of the early phase of acute urate nephropathy.

Authors:  J D Conger; S A Falk; S J Guggenheim; T J Burke
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

5.  Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome.

Authors:  Christina A Hickey; T James Beattie; Jennifer Cowieson; Yosuke Miyashita; C Frederic Strife; Juliana C Frem; Johann M Peterson; Lavjay Butani; Deborah P Jones; Peter L Havens; Hiren P Patel; Craig S Wong; Sharon P Andreoli; Robert J Rothbaum; Anne M Beck; Phillip I Tarr
Journal:  Arch Pediatr Adolesc Med       Date:  2011-07-22

6.  A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Authors:  S C Goldman; J S Holcenberg; J Z Finklestein; R Hutchinson; S Kreissman; F L Johnson; C Tou; E Harvey; E Morris; M S Cairo
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  Rasburicase improves hyperuricemia in infants with acute kidney injury.

Authors:  David J Hobbs; Julia M Steinke; Jin Y Chung; Gina-Marie Barletta; Timothy E Bunchman
Journal:  Pediatr Nephrol       Date:  2009-11-21       Impact factor: 3.714

8.  The hemolytic-uremic syndrome.

Authors:  C Brasher; R L Siegler
Journal:  West J Med       Date:  1981-03

9.  Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.

Authors:  S De Angelis; A Noce; L Di Renzo; R Cianci; A Naticchia; G F Giarrizzo; F Giordano; C Tozzo; G Splendiani; A De Lorenzo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2007 May-Jun       Impact factor: 3.507

Review 10.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

View more
  8 in total

1.  Is it the right time to subject children with acute kidney injury to rasburicase trials?

Authors:  Tomasz Jarmoliński; Marcin Zaniew; Joanna Tousty; Dariusz Runowski
Journal:  Pediatr Nephrol       Date:  2012-03-14       Impact factor: 3.714

2.  Hyperuricemia in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo
Journal:  Pediatr Nephrol       Date:  2012-05-23       Impact factor: 3.714

3.  Cyanosis in a male Nigerian infant with acute kidney injury: answers.

Authors:  Jasmin Pansy; Christoph J Mache; Gerfried Zobel; Gernot Grangl; Ekkehard Ring; K Martin Hoffmann
Journal:  Pediatr Nephrol       Date:  2013-08-30       Impact factor: 3.714

Review 4.  Uric acid and the kidney.

Authors:  Sahar A Fathallah-Shaykh; Monica T Cramer
Journal:  Pediatr Nephrol       Date:  2013-07-04       Impact factor: 3.714

5.  Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Battaglia; Ismael Toledo; Laura Beaudoin; Sandra Mariel Martin; Nicolás Ariel Grisolía; Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2022-10-13       Impact factor: 3.651

6.  Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.

Authors:  Alejandro Balestracci; Luciana Meni Battaglia; Sandra Mariel Martin; Ismael Toledo
Journal:  Pediatr Nephrol       Date:  2020-03-09       Impact factor: 3.714

Review 7.  Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.

Authors:  Nael Alakel; Jan Moritz Middeke; Johannes Schetelig; Martin Bornhäuser
Journal:  Onco Targets Ther       Date:  2017-02-02       Impact factor: 4.147

8.  Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.

Authors:  John K Crane
Journal:  Gut Microbes       Date:  2013-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.